INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Most active filers · 30d

  1. 01Kurtz George0B / 239S · 10 late239 trades$59.22M
  2. 02SPSaba Capital Management, L.P.68B / 23S · 14 late91 trades$30.01M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07CFCheng Chi Fung0B / 42S42 trades$15.33M
  8. 08RJRubinstein Julie0B / 37S37 trades$6.25M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
  4. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  5. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  6. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  7. SELLADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
  8. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K

Form 4 transactions

19,215 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$6,160
145 sh
Apr 2, 2026Apr 3, 2026
Page 307 of 481
← PrevNext →
traded Apr 2, 2026
+1d
SEC Form 4

Evidence

8
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$7,211
179 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

8
SS
Sahni Sanjeev SinghPresident
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$4,078
96 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

8
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$21K
509 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

8
SS
Sahni Sanjeev SinghPresident
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$5,030
124 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

8
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$2,677
63 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

8
SS
Sahni Sanjeev SinghPresident
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$37K
891 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

8
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$5,184
127 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

7
KA
Kerdman AlinaSVP, Controller & CAO
CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP
Open-market sale · 10b5-1 plan
SELL$12K
194 sh
Apr 2, 2026Apr 3, 2026
traded Apr 2, 2026
+1dSEC Form 4

Evidence

5
SG
Steele Richard GSVP - General Counsel
MCOMOODYS CORP /DE/
Open-market sale · 10b5-1 plan
SELL$15K
34 sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC Form 4

Evidence

1
MA
Majalya Sidney A.SVP, CLO and Secretary
TNETTRINET GROUP, INC.
Open-market sale · 10b5-1 plan
SELL$29K
775 sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC Form 4

Evidence

1
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$211K
1,048 sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC Form 4

Evidence

1
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$202K
1,000 sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC Form 4

Evidence

1
RK
Ruddy Marcella K.Chief Medical Officer
TECXTectonic Therapeutic, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
1,000 sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC Form 4

Evidence

1
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$194K
952 sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC Form 4

Evidence

26
MM
Mindlin Damian MiguelVice President
PAMPampa Energy Inc.
Open-market sale
SELL$1.78M
500.0K sh
Mar 31, 2026Apr 2, 2026
traded Mar 31, 2026
+2dSEC Form 4

Evidence

26
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$332K
11.4K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

24
PE
Perros EvangelosChief Financial Officer
PGYPagaya Technologies Ltd.
Open-market sale
SELL$147K
13.0K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

23
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$101K
3,348 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

22
MI
Mecklenburg Gabriel M.I.Director, Exec. Chairman & Co-Founder
HNGEHinge Health, Inc.
Open-market sale · 10b5-1 plan
SELL$1.90M
49.3K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

22
RV
Raghunathan VivekSVP, Engineering
SNOWSnowflake Inc.
Open-market sale · 10b5-1 plan
SELL$592K
3,876 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

21
LW
Lozinski Jeffrey William10% Owner
KSEZKinetic Seas Inc.
Open-market sale
SELL$2,160
61.7K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

21
LW
Lozinski Jeffrey William10% Owner
KSEZKinetic Seas Inc.
Open-market sale
SELL$1,500
50.0K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

20
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,320
300 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

17
BM
Beneski Benjamin MachinasSVP, Chief Technical Officer
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL$7,168
2,867 sh
Mar 31, 2026Apr 2, 2026
traded Mar 31, 2026
+2dSEC Form 4

Evidence

15
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$65K
2,200 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

13
MI
Mecklenburg Gabriel M.I.Director, Exec. Chairman & Co-Founder
HNGEHinge Health, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
668 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,101
300 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC Form 4

Evidence

0
SE
Schubach Sarah ElizabethChief Accounting Officer
DBXDROPBOX, INC.
Open-market sale · 10b5-1 plan
SELL$32K
1,416 sh
Mar 31, 2026Apr 2, 2026
traded Mar 31, 2026
+2dSEC Form 4

Evidence

51
ZR
Zagari RaffaeleDirector
SBLKStar Bulk Carriers Corp.
Open-market sale
SELL$2.62B
11.5K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

38
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$186K
5,985 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

38
DZ
Davis ZachEVP & CFO
LNGCheniere Energy, Inc.
Open-market sale
SELL$8.70M
29.0K sh
Mar 30, 2026Apr 1, 2026
traded Mar 30, 2026
+2dSEC Form 4

Evidence

35
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$8,857
286 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

35
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$26K
819 sh
Mar 23, 2026Apr 1, 2026
traded Mar 23, 2026
+9dSEC Form 4

Evidence

34
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$62K
1,984 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

34
LC
Longhito ChristopherFMR SVP & CSCO
GICGLOBAL INDUSTRIAL Co
Open-market sale
SELL$91K
2,927 sh
Mar 27, 2026Apr 1, 2026
traded Mar 27, 2026
+5dSEC Form 4

Evidence

32
BJ
Buonanno Franck JeanVice-President, Global Sales
LAESSEALSQ Corp
Open-market sale · 10b5-1 plan
SELL$24K
10.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

32
PK
Puylaert KevinChief Sales Officer
SOPHSOPHiA GENETICS SA
Open-market sale
SELL$14.13
3 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.65M
19.5K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$5.02M
59.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC Form 4

Evidence